Guggenheim analyst Yatin Suneja upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Buy.
Guggenheim Upgrades AnaptysBio to Buy
Guggenheim analyst Yatin Suneja upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Buy.
Related Posts
HC Wainwright & Co. Maintains Buy on Aadi Bioscience, Lowers Price Target to $48
HC Wainwright & Co. analyst Robert Burns maintains Aadi Bioscience (NASDAQ:AADI) with a Buy and lowers the price target from $49 to $48.
Analyst Ratings for Dun & Bradstreet Hldgs
Dun & Bradstreet Hldgs (NYSE:DNB) has observed the following analyst ratings within the last quarter:
Recap: Acuity Brands Q4 Earnings
Acuity Brands (NYSE:AYI) reported its Q4 earnings results on Tuesday, October 4, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
Earnings
Acuity Brands beat estimated earnings by 10.34%, reporting an EPS of $3.95 versus an estimate of $3.58.